“Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter.”,” the firm’s analyst commented.
A number of other research firms also recently weighed in on PODD. Oppenheimer Holdings, Inc. restated a hold rating on shares of Insulet Corporation in a report on Saturday, July 22nd. Canaccord Genuity reaffirmed a hold rating and set a $50.00 price target (up from $42.00) on shares of Insulet Corporation in a research note on Tuesday, July 11th. Jefferies Group LLC reaffirmed a buy rating and set a $48.00 price target on shares of Insulet Corporation in a research note on Friday, July 14th. Cowen and Company reaffirmed a buy rating and set a $52.00 price target on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, BTIG Research cut shares of Insulet Corporation from a buy rating to a neutral rating in a research note on Monday, July 17th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $50.46.
Insulet Corporation (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $110 million for the quarter, compared to the consensus estimate of $106.23 million. Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. Insulet Corporation’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) EPS. Equities analysts forecast that Insulet Corporation will post ($0.50) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Insulet Corporation (PODD) Stock Rating Reaffirmed by Northland Securities” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/19/insulet-corporation-podd-receives-buy-rating-from-northland-securities-updated.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. raised its position in shares of Insulet Corporation by 2.0% in the first quarter. UBS Asset Management Americas Inc. now owns 192,168 shares of the medical instruments supplier’s stock worth $8,281,000 after buying an additional 3,775 shares during the last quarter. Swiss National Bank raised its position in shares of Insulet Corporation by 1.9% in the first quarter. Swiss National Bank now owns 94,300 shares of the medical instruments supplier’s stock worth $4,063,000 after buying an additional 1,800 shares during the last quarter. Geneva Advisors LLC raised its stake in Insulet Corporation by 4.3% in the first quarter. Geneva Advisors LLC now owns 21,711 shares of the medical instruments supplier’s stock worth $936,000 after buying an additional 886 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in Insulet Corporation by 28.6% in the first quarter. Tocqueville Asset Management L.P. now owns 45,000 shares of the medical instruments supplier’s stock worth $1,939,000 after buying an additional 10,000 shares during the last quarter. Finally, Rockefeller Financial Services Inc. raised its stake in Insulet Corporation by 2.1% in the first quarter. Rockefeller Financial Services Inc. now owns 369,860 shares of the medical instruments supplier’s stock worth $15,937,000 after buying an additional 7,692 shares during the last quarter.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
What are top analysts saying about Insulet Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insulet Corporation and related companies.